AgingResearch.News
Scientific Reports

A comprehensive German claims data analysis of care pathways, risk factors and comorbidities among acetylcholinesterase inhibitor initiators in Alzheimer's disease

By Christopher Maas, Laura Fang, Elke Mathey, Show 5 more authorsChristine A. F. Von Arnim
Fig. 1. Study design. This figure displays the observation periods for the pre‑ and post‑acetylcholinesterase inhibitor (AChE-I) initiator cohorts, showing the observation windows for the pre-cohort (up to…
Open the figure at full size
Fig. 1. Study design. This figure displays the observation periods for the pre‑ and post‑acetylcholinesterase inhibitor (AChE-I) initiator cohorts, showing the…Study design. This figure displays the observation periods for the pre‑ and post‑acetylcholinesterase inhibitor (AChE-I) initiator cohorts, showing the observation windows for the pre-cohort (up to 8 years before AChE-I initiation in 2022) and the post-cohort (up to 5 years after…Maas et al.
Cohort study of 2,051 peoplePopulations

Declared ties to: Biogen, Roche, Novo Nordisk and 15 more

Paper

The paper

Christopher Maas, Laura Fang, Elke Mathey, Show 5 more authorsChristine A. F. Von Arnim

PharmaLex GmbH; Universitätsmedizin Göttingen

Scientific Reports, 31 Aug 2026

doi.org/10.1038/s41598-026-67494-xPubMed 42675112

More on Alzheimer's disease